Nevertheless, AcSDKP will emerge as a valuable anti-fibrotic endogenous molecule (Figure 6) with the potential to cure devastating fibroproliferative diseases, including diabetic nephropathy. Here, TMSB4X is linked to diabetic kidney disease.